Dr. Christopher Barbieri

Molecular characteristics detected in prostate cancers can provide clues that help predict how the disease will progress, according to new research from investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Dr. Jonathan Shoag, a urologic oncology fellow and instructor of urology at Weill Cornell Medicine, has been named a winner of this year’s prestigious Damon Runyon Physician-Scientist Training Award.

The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that the gene, once deleted, helps to promote tumorous growth.

Conventional wisdom suggests that a high level of the protein prostate specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers.

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth.

Dr. Christopher Barbieri was the type of kid who would press every button in the house, much to his parents’ chagrin. Ultimately he learned to put that inquisitiveness to good use as a doctor and scientist, and discovered a new form of prostate cancer.